Adicet Bio Inc
NASDAQ:ACET
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Adicet Bio Inc
NASDAQ:ACET
|
US |
|
I
|
Ivanhoe Mines Ltd
F:IYAA
|
CA |
|
V
|
Valneva SE
XETRA:AYJ
|
FR |
|
C
|
Crown Castle Inc
SWB:8CW
|
US |
|
L
|
Lantheus Holdings Inc
SWB:0L8
|
US |
|
Natwest Group PLC
LSE:NWG
|
UK |
|
G
|
General Motors Co
BMV:GM
|
US |
|
R
|
Remgro Ltd
SWB:RE7
|
ZA |
|
R
|
Rollins Inc
SWB:RLS
|
US |
|
Axcelis Technologies Inc
NASDAQ:ACLS
|
US |
|
D
|
DSV A/S
DUS:DS81
|
DK |
|
A
|
Aedifica NV
SWB:AOO
|
BE |
|
Nippon Yusen KK
TSE:9101
|
JP |
|
Henderson Land Development Co Ltd
HKEX:12
|
HK |
|
U
|
USANA Health Sciences Inc
XMUN:USJ
|
US |
|
China CSSC Holdings Ltd
SSE:600150
|
CN |
|
S
|
ServiceNow Inc
SWB:4S0
|
US |
|
Kirin Holdings Co Ltd
TSE:2503
|
JP |
|
C
|
CBRE Group Inc
XBER:RF6
|
US |
|
T
|
TQM Alpha PCL
SET:TQM
|
TH |
|
H
|
Hochtief AG
XMUN:HOT
|
DE |
|
R
|
Robit Oyj
OMXH:ROBIT
|
FI |
|
Asahi Kasei Corp
OTC:AHKSY
|
JP |
|
M
|
MTR Corp Ltd
SWB:MRI
|
HK |
Adicet Bio Inc
Adicet Bio is a clinical-stage biotechnology company that develops cell therapies made from donor immune cells, especially gamma delta T cells. Its goal is to create “off-the-shelf” treatments that can be given to patients without having to collect and engineer each patient’s own cells. The company’s main work is research and development of these therapies for cancers and, more recently, autoimmune diseases. Adicet does not sell a broad commercial product line. It advances drug candidates through laboratory work and clinical testing, then seeks partnerships, licensing deals, or future product sales if a therapy reaches the market. In practice, its customers are not end users today but hospitals, doctors, and eventually patients, while its near-term economic value comes from funding, collaborations, and the long-term possibility of approved medicines. What makes Adicet different is its focus on allogeneic cell therapy, which is designed to be manufactured in advance and used more like a standard drug than a custom treatment. That could make cell therapy easier to scale and distribute if the science works. The company sits in a high-risk, high-science part of biotech where success depends on turning a complex immune-cell platform into safe and effective medicines.
Adicet Bio is a clinical-stage biotechnology company that develops cell therapies made from donor immune cells, especially gamma delta T cells. Its goal is to create “off-the-shelf” treatments that can be given to patients without having to collect and engineer each patient’s own cells. The company’s main work is research and development of these therapies for cancers and, more recently, autoimmune diseases.
Adicet does not sell a broad commercial product line. It advances drug candidates through laboratory work and clinical testing, then seeks partnerships, licensing deals, or future product sales if a therapy reaches the market. In practice, its customers are not end users today but hospitals, doctors, and eventually patients, while its near-term economic value comes from funding, collaborations, and the long-term possibility of approved medicines.
What makes Adicet different is its focus on allogeneic cell therapy, which is designed to be manufactured in advance and used more like a standard drug than a custom treatment. That could make cell therapy easier to scale and distribute if the science works. The company sits in a high-risk, high-science part of biotech where success depends on turning a complex immune-cell platform into safe and effective medicines.
Revenue Decline: ACETO reported first quarter net sales of $164.4 million, down 11.3% from the prior year as Human Health sales dropped sharply due to generic market pressures and failure to supply (FTS) penalties.
Widening Loss: The company posted a net loss of $21.1 million, or $0.59 per share, compared to $0.5 million net income last year, driven by falling gross profit and higher SG&A expenses.
Segment Divergence: Pharmaceutical Ingredients and Performance Chemicals segments showed year-over-year growth in sales and gross profit, while Human Health continued to struggle.
Cash Position & Liquidity: Cash and equivalents were $52.5 million, with total debt at $315.4 million; management emphasized reliance on a strategic alternatives process to generate liquidity and retire debt.
Inventory Build: Inventory rose to $156.5 million, primarily to improve supply reliability and mitigate tariff risks, causing a large cash draw.
Tariff Exposure: Tariffs on Chinese imports have had a limited impact so far, but could cost $850,000 to $3.7 million in the second half of fiscal 2019 if rates rise to 25%.
Failure to Supply Improving: FTS claims and backorders have declined sharply after operational changes, with further improvement expected.
Strategic Review Ongoing: The board continues a strategic alternatives review but offered no new details, affirming intent to use proceeds to retire debt.
